# Mortality-incidence ratio as an estimate of five-year cancer survival in Metropolitan Lima

Source: https://onco.cc/key-papers/paper-stenning-persivale-mir-survival-lima-ecancer-2018/  
OnCo record `paper-stenning-persivale-mir-survival-lima-ecancer-2018` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Using the Lima cancer registry's 2004 to 2005 cases linked to the national identity register, the authors found that one minus the mortality-incidence ratio closely tracked observed five-year survival for ten common cancers in Lima.

## Summary

Published as "The mortality-incidence ratio as an indicator of five-year cancer survival in metropolitan Lima". The authors took new cases and deaths for breast, stomach, prostate, thyroid, lung, colon, cervical and liver cancer, non-Hodgkin lymphoma and leukaemia from the Registro de Cáncer de Lima Metropolitana for 2004 to 2005, checked each case's vital status at five years in the national identity and civil status register (RENIEC), and compared observed five-year survival with the complement of the mortality-incidence ratio.

## Fields

- Kind: Key paper
- Last checked: 2026-11-11
- Journal: Ecancermedicalscience
- Year: 2018
- DOI: 10.3332/ecancer.2018.799
- Authors: Stenning-Persivale K, Franco MJS, Cordero-Morales A, et al.
- Findings: Observed and estimated five-year survival were 66.7% and 86.7% for thyroid cancer, 69.6% and 68% for breast, 64.3% and 63.8% for prostate, and 50.1% and 58.5% for cervical cancer.; Pearson's r for the correlation between the two measures was 0.9839, and the ratio captured 96.82% of observed survival.
- What it means: The authors conclude that one minus the mortality-incidence ratio is an appropriate way to approximate five-year survival for these ten cancers in Lima. The registry's 2013 to 2015 report tabulates that figure for each cancer.
- Caveats: Cases diagnosed in 2004 to 2005 in Lima only.; The estimate was far from observed survival for thyroid cancer.

## Sources

- Ecancermedicalscience 2018: https://doi.org/10.3332/ecancer.2018.799
- PubMed: https://pubmed.ncbi.nlm.nih.gov/29456616/

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- institutions: [Instituto Nacional de Enfermedades Neoplásicas](https://onco.cc/institutions/inen-peru/), [Registro de Cáncer de Lima Metropolitana (Metropolitan Lima Cancer Registry)](https://onco.cc/institutions/lima-metropolitan-cancer-registry/)

---
JSON: https://onco.cc/api/v1/entities/paper-stenning-persivale-mir-survival-lima-ecancer-2018.json